Data were entered onto SPPS (v21), with results analysed using d

Data were entered onto SPPS (v.21), with results analysed using descriptive statistics. Talazoparib concentration The questions derived from the Morisky tool were used to generate an adherence score for each patient, with scores of 2 or more representing high knowledge and motivation for anticoagulation adherence. Seventy-one of seventy-eight approached patients completed the questionnaire; fifty-seven (80%) were prescribed

warfarin, most commonly for atrial fibrillation, with fifty-one patients (72%) having been on treatment for >28 days. Eight patients (11%) reported occasionally missing their anticoagulation medicine and the majority (sixty-seven patients, 94%) were confident they took their anticoagulant correctly. Twenty-seven patients (38%) said they did not know about the long term benefits of taking anticoagulant therapy. The same number stated that they had concerns about their anticoagulation medication, with possible side-effects and long-term damage to health most commonly cited. Sixty-four patients responded to the questions required for a Morisky score to be calculated (Table 1). Table 1 Morisky scores for patients completing the questionnaire; higher scores indicate greater adherence Morisky

score 3 4 5 6 N/A N (%) 2 (2.5) 4 (5.5) 24 (34) 34 (48) 7 (10) Pharmacists believed that 20% of patients required further Selleckchem GSK 3 inhibitor adherence support, however

no significant differences were found in the Morisky scores of these patients and those patients considered ID-8 adherent by the pharmacist. Clinic pharmacists reported using information from the questionnaire for thirty-one (44%) consultations. Our findings suggest that the majority of patients attending the anticoagulation clinic had high knowledge and motivation to adhere to their anticoagulant therapy. Some patients expressed concerns surrounding treatment, possibly reflected by the similar number of patients who were relatively new to anticoagulation therapy. Several patients were thought to need targeted adherence support by the pharmacist, but this was not reflected by their Morisky scores from the questionnaire. This mismatch warrants further exploration in a larger study. The tool may not be practical for administration to all patients in clinic, but could be used to determine non-adherent patients and possible reasons for their non-adherence. 1. Cutler DM, Everett W. Thinking outside the pillbox – medication adherence as a priority for healthcare reform. NEJM 2010; 362: 1553–1555 2. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67–74 C. Beea, S. Gardinera, G. Maya,b, D.

This entry was posted in Antibody. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>